Regeneron Pharmaceuticals
A Principal Scientist leading the development of therapies for hearing loss and vestibular disorders, independently directing research projects and advancing preclinical drug discovery programs. The role drives translational studies and novel therapeutic development while mentoring junior scientists and collaborating across functions.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Principal Scientist II - Pharmacology
lifelancer
Principal Scientist Metabolism Bioscience Research, CVRM
AstraZeneca
Senior Scientist, Cancer Immunology Translational Research
Bristol Myers Squibb
Preclinical Pharmacokinetics Scientist
Orion Pharma
Principal Research Scientist II, Immunology Discovery Research
AbbVie
Senior Director, In Vivo Pharmacology
Generate:Biomedicines